期刊文献+

三氧化二砷对胃癌细胞SGC7901多药耐药的逆转作用及其机制 被引量:10

Reversal effect and mechanism of arsenic trioxide on multidrug resistance of gastric carcinoma cells SGC7901
下载PDF
导出
摘要 研究三氧化二砷(arsenic trioxide,As2O3)对胃癌细胞多药耐药的逆转作用及其机制。逐渐递增长春新碱(VCR)的浓度诱导胃癌细胞株SGC7901产生多药耐药性(SGC7901/VCR)。MTT法测定药物对肿瘤细胞的杀伤作用;Western blotting检测肿瘤细胞内P-糖蛋白(P-gp)、谷胱甘肽S-转移酶(GST-s)表达。结果表明,胃癌SGC7901/VCR细胞对长春新碱(VCR)、5-氟尿嘧啶(5-Fu)及表阿霉素的耐药倍数分别为16.56倍、2.69倍及13.05倍。经As2O3预处理24 h后,长春新碱、5-氟尿嘧啶及表阿霉素对SGC7901/VCR的耐药倍数显著下降(P<0.05)。SGC7901/VCR在静息时细胞内P-gp、GST-s蛋白表达显著高于SGC7901。而As2O3可使SGC7901/VCR细胞内P-gp、GST-s蛋白表达显著下降,但是对SGC7901无明显作用。从而证实As2O3部分逆转SGC7901/VCR的耐药性,其机制可能与P-gp、GST-s蛋白表达降低有关。 The purpose of this study is to investigate the reversal effect and its mechanism of arsenic trioxide (As2O3) on muhidrug resistance of gastric carcinoma ceils. The concentration of vincristine (VCR) increased gradually to induce the drug resistance of gastric carcinoma cell SGC7901. MTT assay was used to determine the lethal effect of anticarcinogens on tumor cells and Western blotting assay was applied to determine the expression of P-glucoprotein (P-gp) and glutathione S-transferase (GST-s) in tumor ceils. As a result, the resistance of SGC7901/VCR ceils to VCR, fluorouracil and epirubicin was 16.56, 2.69 and 13.05 times, respectively, more than that of SGC7901 ceils. After 24 h precondition with As2O3, RI of vincristine, fluorouracil and epirubicin decreased significantly (P 〈0.05). Expression of P-gp and GST-s in resting SGC7901/VCR ceils was significantly higher than that in carcinogen-sensitive SGC7901 ceils. As2O3 decreased the expression of P-gp and GST-s in SGC7901/VCR ceils significantly, while it showed no significant effect on carcinogen-sensitive SGC7901 ceils. The result suggested that As2O3 could partly reverse drug resistance of SGC7901/VCR ceils by probably the mechanism of decreasing the expression of P-gp and GST-s.
出处 《药学学报》 CAS CSCD 北大核心 2007年第9期949-953,共5页 Acta Pharmaceutica Sinica
关键词 胃癌 多药耐药 三氧化二砷 gastric carcinoma muhidrug resistance arsenic trioxide
  • 相关文献

参考文献7

二级参考文献49

  • 1孙洪德,中国中西医结合杂志,1992年,12卷,170页
  • 2孙关林,中华血液学杂志,1992年,3卷,135页
  • 3张之南,血液病诊断及疗效标准,1991年
  • 4团体著者,药材学,1960年
  • 5Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein) : recent advances andclinical relevance[ J ]. Clin Pharmacol Ther, 2004,75(1):13-33.
  • 6Zhang Y, Benet LZ. The gut as a barrier to drug absorption : combined role of cytochrome P450 3A and P-glycoprotein[ J ]. Clin Pharmacokinet, 2001,40 ( 3 ) :159 - 168.
  • 7Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications [ J ]. Clin Pharmacokinet, 2003,42( 1 ) :59 -98.
  • 8Ambudkar SV, Dey S, Hrycyna CA, et al. Biochemical,cellular, and pharmacological aspects of the multidrug transporter[J]. Annu Rev Pharmacol Toxicol, 1999,39 :361 - 398.
  • 9Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter [ J ].Annu Rev Pharmacol Toxicol , 2003,43:285 - 307.
  • 10Mizuno N, Niwa T, Yotsumoto Y, et al. Impact of drug transporter studies on drug discovery and development[J]. Pharmacol Rev, 2003,55(3):425 -461.

共引文献686

同被引文献112

引证文献10

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部